Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma (Oncogene, (2022), 41, 21, (2973-2983), 10.1038/s41388-022-02305-x)

  • Patience Odeniyide
  • , Marielle E. Yohe
  • , Kai Pollard
  • , Angelina V. Vaseva
  • , Ana Calizo
  • , Lindy Zhang
  • , Fausto J. Rodriguez
  • , John M. Gross
  • , Amy N. Allen
  • , Xiaolin Wan
  • , Romel Somwar
  • , Karisa C. Schreck
  • , Linda Kessler
  • , Jiawan Wang
  • , Christine A. Pratilas

Research output: Contribution to journalComment/debatepeer-review

3 Scopus citations

Abstract

Following the publication of this article a number of copy editing omissions were noted. These have now been corrected.

Original languageEnglish (US)
Pages (from-to)3037
Number of pages1
JournalOncogene
Volume41
Issue number21
DOIs
StatePublished - May 20 2022

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Fingerprint

Dive into the research topics of 'Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma (Oncogene, (2022), 41, 21, (2973-2983), 10.1038/s41388-022-02305-x)'. Together they form a unique fingerprint.

Cite this